Oseltamivir (Tamiflu): Clinical Overview
Oseltamivir is an oral neuraminidase inhibitor approved for treatment and prophylaxis of influenza A and B in patients aged 1 year and older, with weight-based dosing in children and renal dose adjustments required for creatinine clearance <30 mL/min.
Indications
Oseltamivir is indicated for:
- Treatment of influenza in patients ≥1 year who have been symptomatic for ≤48 hours 1
- Prophylaxis of influenza in patients ≥1 year 1
Critical limitation: Efficacy is not established when treatment begins >48 hours after symptom onset. This is not a substitute for annual influenza vaccination 1.
Dosing Regimens
Treatment (5 days)
Adults and adolescents (≥13 years): 75 mg twice daily 2, 3, 4, 1
Pediatric patients (≥1 year) - Weight-based dosing 2, 3, 4:
- <15 kg: 30 mg twice daily
- 15-23 kg: 45 mg twice daily
- 23-40 kg: 60 mg twice daily
- >40 kg: 75 mg twice daily
Infants 9-11 months: 3.5 mg/kg/dose twice daily 3
Term infants 3-8 months: 3 mg/kg/dose twice daily 3, 4
Term infants 0-3 months: 3 mg/kg/dose twice daily (treatment only; limited safety data) 2, 4
Preterm infants - Dosing based on postmenstrual age (gestational age + chronological age) 3:
- <38 weeks postmenstrual age: 1.0 mg/kg/dose twice daily
- 38-40 weeks postmenstrual age: 1.5 mg/kg/dose twice daily
- >40 weeks postmenstrual age: 3.0 mg/kg/dose twice daily
Prophylaxis (10 days post-exposure; up to 6 weeks for community outbreak)
Adults and adolescents (≥13 years): 75 mg once daily 2, 3, 4, 1
Pediatric patients (≥1 year): Same weight-based doses as treatment, but once daily instead of twice daily 2, 3, 4
Infants 3-11 months: 3-3.5 mg/kg/dose once daily 3
Infants <3 months: Not recommended for prophylaxis unless situation judged critical due to limited data 2, 4
Formulations and Administration
- Capsules: 30 mg, 45 mg, 75 mg 2, 3, 1
- Oral suspension: Powder reconstituted to 6 mg/mL final concentration 3, 4
- 30 mg dose = 5 mL
- 45 mg dose = 7.5 mL
- 60 mg dose = 10 mL
- 75 mg dose = 12.5 mL
Administration: Can be taken without regard to meals, though administration with meals improves gastrointestinal tolerability 2, 3. If commercial suspension unavailable, capsules may be opened and mixed with sweetened liquid, or pharmacies can compound suspension 2, 3.
Renal Dose Adjustments
For creatinine clearance 10-30 mL/min 2, 3, 1:
Treatment: 75 mg once daily for 5 days (instead of twice daily)
Prophylaxis:
- 30 mg once daily for 10 days, OR
- 75 mg once every other day for 10 days (5 total doses)
No dose adjustment needed for creatinine clearance >30 mL/min or based on age alone 5.
Important caveat: Current FDA-approved renal dosing recommendations may result in subtherapeutic concentrations early in infection for patients with mild-moderate renal impairment. Consider using standard first dose (75 mg) followed by reduced maintenance doses to achieve therapeutic levels more rapidly 6, 7.
Contraindications
Absolute contraindication: Known serious hypersensitivity to oseltamivir or any component 1
Adverse Effects
Most common (>1% and more common than placebo) 1:
- Treatment studies: Nausea, vomiting
- Prophylaxis studies: Nausea, vomiting, diarrhea, abdominal pain
Gastrointestinal effects are mild and transient, reduced when taken with food 5, 8, 9.
Serious but rare:
- Neuropsychiatric events: Patients with influenza, particularly pediatric patients, may be at increased risk of confusion or abnormal behavior early in illness. Monitor for signs of abnormal behavior 1. This association remains unclear as influenza itself causes neuropsychiatric symptoms 9.
- Serious skin/hypersensitivity reactions: Discontinue if allergic-like reactions occur 1
- Anaphylaxis: Reported postmarketing 4
Safety profile: Extensive postmarketing surveillance (>4 million prescriptions) shows no increased risk of cardiac, neuropsychiatric, or respiratory events compared to non-users 9. Electrocardiogram parameters including QTc interval are unaffected even at high doses 9.
Drug Interactions
Live attenuated influenza vaccine (intranasal) 1:
- Do not administer vaccine until 48 hours after stopping oseltamivir
- Do not administer oseltamivir until 2 weeks after vaccine administration (unless medically indicated)
No significant drug-drug interactions due to simple pharmacology 9.
Special Populations
Pregnancy: No data in pregnant women. Use only if clearly needed 1.
Nursing mothers: Caution should be exercised 1.
Pediatric use: Safety and efficacy not established in patients <1 year old per FDA labeling, though guidelines support use in infants based on Emergency Use Authorization data and clinical experience 2, 4, 10.
Elderly: No dose reduction based on age alone, but assess renal function as it declines with aging 5.
Large body mass: Standard dosing may be inadequate. Consider proportionately larger first dose with therapeutic drug monitoring if available 6.
Clinical Considerations
When to treat: Initiate within 48 hours of symptom onset for maximum benefit. Earlier initiation (within 12-24 hours) associated with faster resolution 8, 11. Recent evidence shows oseltamivir reduces in-hospital mortality by 1.8%, increases likelihood of earlier discharge, and reduces 30-day readmission in hospitalized patients 11.
Resistance: Most influenza strains remain sensitive to oseltamivir. High levels of resistance exist to amantadine and rimantadine, which should not be used 3, 2. Monitor local surveillance data for resistance patterns 2, 3.
Common pitfall: Clinicians show significant nonadherence to guidelines for hospitalized children, with treatment recommended in only ~50% of cases meeting criteria 12. All hospitalized patients with confirmed or suspected influenza should receive oseltamivir regardless of symptom duration per current guidelines, though this recommendation is based on observational data rather than randomized trials 12, 11.
Premature infants: Require specialized dosing based on postmenstrual age due to immature renal function. Consult pediatric infectious disease for extremely preterm infants (<28 weeks) 3.